UK regulator rules benefits of lecanemab do not justify the cost
Drug Discovery World
AUGUST 29, 2024
The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. Diana Spencer, Senior Digital Content Editor, DDW The post UK regulator rules benefits of lecanemab do not justify the cost appeared first on Drug Discovery World (DDW).
Let's personalize your content